Craig A. Dionne, PhD, is one of our founders and has served on our board since November 2003. He has over 25 years of experience in the pharmaceutical industry, including direct experience in identifying promising oncology treatments and bringing them through the clinic. He served for several years as VP Discovery Research at Cephalon, Inc. (now Teva Pharmaceuticals), a biopharmaceutical company, where he was responsible for its oncology and neurobiology drug discovery and development programs. Dr. Dionne also served as Executive Vice President at the Prostate Cancer Research Foundation. In addition to extensive executive experience, Dr. Dionne's productive scientific career has led to six issued patents and co-authorship of many scientific papers. Dr. Dionne received his PhD from the University of Texas at Austin in 1984.

Russell B. Richerson, PhD, joined GenSpera in September 2009. He has over 25 years of experience in the Biotechnology/Diagnostics industry, including 11 years at Abbott Laboratories in numerous management roles. He also has extensive experience in senior research and development positions at companies such as Boehringer Mannheim, Du Pont, Prometheus Laboratories, Ventana Medical Systems, and the Molecular Profiling Institute. Dr. Richerson recently served on the board of the International Genomics Consortium (IGC), a non-profit medical research organization located in Phoenix, Arizona. Dr. Richerson received his PhD from the University of Texas at Austin in 1983

Peter E. Grebow, PhD, joined the board in May 2012. He currently is President and founder of P.E. Grebow Consulting, Inc., which he formed in 2011. He has also served as Executive Vice President of Research and Development at Eagle Pharmaceuticals, Inc. since October 2013. Before becoming a director at GenSpera, Dr. Grebow held several key positions with Cephalon, Inc., including Executive Vice President of Cephalon Ventures, Executive Vice President of Technical Operations, Senior Vice President of Worldwide Business Development and Senior Vice President of Drug Development. Prior to joining Cephalon, Dr. Grebow served as Vice President Drug Development for Rorer Central Research, a division of Rhone-Poulenc Rorer Pharmaceuticals Inc., and as director of Optimer Pharmaceuticals (NASDAQ: OPTR) . Since 2011, he has held directorships at Q Holdings, Inc., and Complexa, Inc. Dr. Grebow received his PhD in physical biochemistry from the University of California, Santa Barbara, in 1973.

Dr. Bo Jesper Hansen, MD, PhD Founded Scandinavian Medical Research, during which company Dr. Hansen served as Medical Advisor for Synthélabo, Pfizer, Inc., Pharmacia Corporation and Yamanouchi Pharmaceutical Co. Ltd.

He served as Chief Executive Officer and President of Swedish Orphan International AB (SOI AB) from 1998 to 2010 and also served as a Director of the Board of Swedish Orphan International AB during the same period, until the acquisition by Biovitrum AB in January 2010, forming Swedish Orphan Biovitrum (SOBI; NASDAQ:OMX). Dr. Hansen has been with Swedish Orphan International AB since 1993, where he grew it from a small Nordic-focused niche specialty-/Orphan drug pharma to an international organization, with over 60 products across Europe.

Prior to joining Swedish Orphan International AB, Dr. Hansen also co-founded the Shared Clinic “The Prostate Clinic” in Denmark.

Dr. Hansen's experience includes orphan drug research and development, international marketing and contract negotiations with extensive knowledge within regulatory, pharmacovigilance, medical marketing and business development, and he has close collaborations in the Orphan Drug area at executive level.

Currently, Dr. Hansen is Executive Chairman of Swedish Orphan Biovitrum AB, Executive Chairman of TopoTarget A/S (TOPO; NASDAQ:OMX) since August, 2012 and has served as its Chairman from April, 2010, untill the merger with BioAlliance SAS in August 2014, forming Onxeo SA/Onxeo A/S; and since October 1, 2013 Chairman of Karolinska Development AB (KDEV; NASDAQ:OMX). He served as a non-executive Director of Gambro AB from august 2010-Dec 2012, when Gambro AB was acquired by Baxter; and as a non-executive Director in Zymenex A/S from 2008 until August 2013, when Zymenex was acquired by Chiesi Pharmaceutici. Furthermore, Dr. Hansen serves as a non-executive Director of Orphazyme ApS, Newron Pharmaceuticals SpA (NWRN; SIX), ABLYNX NV (NYSE Euronext Brussels) and CMC AB. Dr. Hansen is also a non-executive Director of Hyperion Therapeutics (HPTX; NASDAQ), Inc. since April 2011 and Genspera, Inc. (GNSZ; NASDAQ) since August 2010. Dr. Hansen has been a Member of the Supervisory Board at Novagali Pharma S.A. since June 22, 2010 until Dec 2011 when Novagali Pharma S.A. was acquired by Santen. Dr. Hansen also serves as an Expert Evaluator of Calls to the European Commission’s 7th Framework Programme for Research (FP7-HEALTH-2012 and FP7-HEALTH-2013).

He is the author of more than 40 publications in international peer-review scientific journals and is an experienced presenter at international scientific congresses. Dr. Hansen is a Doctor of Medicine and holds an MD and a PhD from the University of Copenhagen.

Scott V. Ogilvie, has served as a director on our board since February 2008. Mr. Ogilvie is currently the President of AFIN International, Inc., an international private equity and strategic advisory firm, which he founded in 2006. Prior to December 31, 2009, he was CEO of Gulf Enterprises International, Ltd, an investment and strategic advisory company with primary activities in the Middle East and North Africa. He held this position since August 2006. Mr. Ogilvie previously served as Chief Operating Officer of CIC Group, Inc., an investment manager, a position he held from 2001 to 2007. He began his career as a corporate and securities lawyer with Hill, Farrer & Burrill, and has extensive public and private corporate management and board experience in finance, real estate, and life science and technology companies. During the past 5 years, Mr. Ogilvie has served on the board of directors of Innovative Card Technologies, Inc. (OTCBB:INVC), Preferred Voice, Inc., (OTCBD:PRFV), GenSpera, Inc. (OTCBB: GNSZ) and Research Solutions, Inc. (OTCBB:RSSS).